Bristol-Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City, develops and market innovative medicines for various disorders. BMS in its present form was formed in 1989, following the merger of its predecessors Bristol-Myers and the Squibb Corporation.
- In Feb 2021, US FDA approved Breyanzi (lisocabtagene maraleucel), a chimeric antigen receptor (CAR) T cell therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. Breyanzi, , is the third gene therapy approved by the FDA for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL).
- In Aug 2019, US FDA approved Inrebic (fedratinib), a highly selective JAK2 inhibitor for the treatment of patients with myelofibrosis.
- In Mar 2015, FDA Expands Approved use of Opdivo (nivolumab) to treat metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
- In Dec 2014, US FDA approved Opdivo (nivolumab) for metastatic melanoma, which can no longer respond to other drugs. Opdivo is the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world.
- In Mar 2011, Ipilimumab/Yervoy™, was approved by FDA for the treatment of metastatic melanoma.
Yervoy, a CTLA-4 immune checkpoint inhibitor, is approved in more than 50 countries for the treatment of patients with advanced melanoma who have received prior therapy, and is in late-stage development as a potential treatment option for melanoma, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). - In Oct 2007, FDA approved Ixabepilone/Ixempra™, for the treatment of aggressive metastatic or locally advanced breast cancer.
- In Jun 2006, FDA granted accelerated approval to Dasatinib/Sprycel®, for the treatment of Ph+ chronic myeloid leukemia.
- In Dec 1992, Paclitaxel/TAXOL® (derived from the bark of Pacific Yew tree), was approved by FDA for treatment of ovarian cancer.
- In Mar 1989, PARAPLATIN® (carboplatin aqueous solution), was approved by FDA for the initial treatment of ovarian cancer.
Page 1 of 2
